α-Synuclein and tau deposition in the central nervous system is responsible for various parkinsonian syndromes, including Parkinson’s disease, multiple system atrophy, dementia with Lewy bodies, progressive supranuclear palsy and corticobasal degeneration. Emerging evidence has suggested that pathologic α-synuclein and tau are transmitted from cell to cell and further accelerate the aggregation of pathologic proteins in neighboring cells. Furthermore, extracellular pathologic proteins have also been reported to provoke inflammatory responses that lead to neurodegeneration. Therefore, immunotherapies targeting extracellular α-synuclein and tau have been proposed as potential disease-modifying strategies. In this review, we summarize completed phase I trials and ongoing phase II trials of immunotherapies against α-synuclein and tau and further discuss concerns and hurdles to overcome in the future.
Citations
Citations to this article as recorded by
Overlaps and divergences between tauopathies and synucleinopathies: a duet of neurodegeneration Wen Li, Jia-Yi Li Translational Neurodegeneration.2024;[Epub] CrossRef
Neurodegenerative disorders: Mechanisms of degeneration and therapeutic approaches with their clinical relevance Dnyandev G. Gadhave, Vrashabh V. Sugandhi, Saurav Kumar Jha, Sopan N. Nangare, Gaurav Gupta, Sachin Kumar Singh, Kamal Dua, Hyunah Cho, Philip M. Hansbro, Keshav Raj Paudel Ageing Research Reviews.2024; 99: 102357. CrossRef
Modeling the dynamics of innate and adaptive immune response to Parkinson's disease with immunotherapy Salma M. Al-Tuwairqi, Asma A. Badrah AIMS Mathematics.2023; 8(1): 1800. CrossRef
Evaluation of an Adoptive Cellular Therapy-Based Vaccine in a Transgenic Mouse Model of α-synucleinopathy Winston T. Chu, Jesse Hall, Anjela Gurrala, Alexander Becsey, Shreya Raman, Michael S. Okun, Catherine T. Flores, Benoit I. Giasson, David E. Vaillancourt, Vinata Vedam-Mai ACS Chemical Neuroscience.2023; 14(2): 235. CrossRef
Direct digital sensing of protein biomarkers in solution Georg Krainer, Kadi L. Saar, William E. Arter, Timothy J. Welsh, Magdalena A. Czekalska, Raphaël P. B. Jacquat, Quentin Peter, Walther C. Traberg, Arvind Pujari, Akhila K. Jayaram, Pavankumar Challa, Christopher G. Taylor, Lize-Mari van der Linden, Titus Nature Communications.2023;[Epub] CrossRef
Inflammation in multiple system atrophy Marta Leńska-Mieciek, Natalia Madetko-Alster, Piotr Alster, Leszek Królicki, Urszula Fiszer, Dariusz Koziorowski Frontiers in Immunology.2023;[Epub] CrossRef
Immunisation with UB-312 in the Thy1SNCA mouse prevents motor performance deficits and oligomeric α-synuclein accumulation in the brain and gut Jacqui T. Nimmo, Harry Smith, Chang Yi Wang, Jessica L. Teeling, James A. R. Nicoll, Ajay Verma, Jean-Cosme Dodart, Zhi Liu, Feng Lin, Roxana O. Carare Acta Neuropathologica.2022; 143(1): 55. CrossRef
Efficacy and immunogenicity of MultiTEP-based DNA vaccines targeting human α-synuclein: prelude for IND enabling studies Changyoun Kim, Armine Hovakimyan, Karen Zagorski, Tatevik Antonyan, Irina Petrushina, Hayk Davtyan, Gor Chailyan, Jonathan Hasselmann, Michiyo Iba, Anthony Adame, Edward Rockenstein, Marcell Szabo, Mathew Blurton-Jones, David H. Cribbs, Anahit Ghochikyan, npj Vaccines.2022;[Epub] CrossRef
Evidence of Inflammation in Parkinson’s Disease and Its Contribution to Synucleinopathy Thuy Thi Lai, Yun Joong Kim, Hyeo-il Ma, Young Eun Kim Journal of Movement Disorders.2022; 15(1): 1. CrossRef
Slowing Parkinson’s Disease Progression with Vaccination and Other Immunotherapies Dhanya Vijayakumar, Joseph Jankovic CNS Drugs.2022; 36(4): 327. CrossRef
Amyloid β, Tau, and α-Synuclein aggregates in the pathogenesis, prognosis, and therapeutics for neurodegenerative diseases Urmi Sengupta, Rakez Kayed Progress in Neurobiology.2022; 214: 102270. CrossRef
Modeling the dynamics of innate immune response to Parkinson disease with therapeutic approach Asma Badrah, Salma Al-Tuwairqi Physical Biology.2022; 19(5): 056004. CrossRef
Potential of food-derived bioactive peptides in alleviation and prevention of Alzheimer's disease Le Zhao, Dan Li, Xiaofen Qi, Kaifang Guan, Haoran Chen, Rongchun Wang, Ying Ma Food & Function.2022; 13(21): 10851. CrossRef
Harnessing the immune system for the treatment of Parkinson’s disease Vinata Vedam-Mai Brain Research.2021; 1758: 147308. CrossRef
The Contribution of Microglia to Neuroinflammation in Parkinson’s Disease Katja Badanjak, Sonja Fixemer, Semra Smajić, Alexander Skupin, Anne Grünewald International Journal of Molecular Sciences.2021; 22(9): 4676. CrossRef
Viral alpha-synuclein knockdown prevents spreading synucleinopathy Sindhu Menon, Rikke H Kofoed, Fadl Nabbouh, Kristiana Xhima, Yasmeen Al-Fahoum, Tammy Langman, Howard T J Mount, Lamya S Shihabuddin, S Pablo Sardi, Paul E Fraser, Joel C Watts, Isabelle Aubert, Anurag Tandon Brain Communications.2021;[Epub] CrossRef
Immunotherapies for Aging-Related Neurodegenerative Diseases—Emerging Perspectives and New Targets Somin Kwon, Michiyo Iba, Changyoun Kim, Eliezer Masliah Neurotherapeutics.2020; 17(3): 935. CrossRef
The Functional Roles and Applications of Immunoglobulins in Neurodegenerative Disease Kyu-Young Sim, Kyeong Chan Im, Sung-Gyoo Park International Journal of Molecular Sciences.2020; 21(15): 5295. CrossRef
Novel antibodies detect additional α-synuclein pathology in synucleinopathies: potential development for immunotherapy Jacqui T. Nimmo, Ajay Verma, Jean-Cosme Dodart, Chang Yi Wang, Jimmy Savistchenko, Ronald Melki, Roxana O. Carare, James A. R. Nicoll Alzheimer's Research & Therapy.2020;[Epub] CrossRef
New Insights Into Drug Discovery Targeting Tau Protein Yoshiyuki Soeda, Akihiko Takashima Frontiers in Molecular Neuroscience.2020;[Epub] CrossRef